Fractal Analytics Optimistic as TMT Bottoms Out

Fractal Analytics Limited — Q1 FY2027 (quarter ended June 30, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly frames the quarter as a “bottoming out” phase in TMT and emphasizes improving demand and execution.
• Strong forward-looking language: “We feel our future is bright”, “We have never been more optimistic”, and “amazing days are ahead of us.”
• Even when acknowledging weakness, they attribute it to identifiable drivers (TMT) and provide a recovery narrative (“expect healthy sequential growth in TMT the next quarter”).

2. Key Themes from Management Commentary

• Growth with a vertical/geography split
• Headline growth driven by Healthcare & Life Sciences (69% YoY) and BFSI (36% YoY); TMT declined 22% YoY and dragged overall growth.
• Europe led growth (+25%) while APAC/others were down (-2%) due to TMT plus Middle East conflict.
• Customer expansion + de-risking
• NPS improved (77 vs 73).
• Net Revenue Retention improved (117% vs 108%).
• New client contribution: new clients contributed 3% of revenue growth; 0% churn from the client base in Q1.
• Concentration reduced: top 10 clients 51.8% of revenue vs 55.9% a year ago.
• Profitability expansion alongside investment
• Gross margin 46%; Adj. EBITDA margin 17% (+189 bps YoY); Net income +92% YoY.
• R&D investment increased: INR 61 crore (+31% YoY), with emphasis on building Cogentiq, Asper, Analytics Vidhya.
• Platform/product momentum (Cogentiq + Fractal Alpha)
• “AI-led transformation deals with Cogentiq across CPG and financial services” are described as a growing revenue engine.
• Cogentiq pipeline described as product-led, with early wins (“more than 10 clients”).
• Asper ARR up 59% to $9m (June 2026), with expectation of stronger 2H due to contract-to-revenue timing.
• Macro/industry narrative: AI spend rising, but execution matters
• Management argues AI is moving into core budgets and that volume compression from AI will be outweighed by multiplication of use cases.
• Competitive intensity is acknowledged as rising, especially in TMT.

3. Q&A Analysis

Theme A: TMT weakness—what’s driving it and what’s the recovery path?

• Core questions
• What drives visibility that TMT is “bottoming out” in 2Q—new deals vs existing clients?
• Is TMT decline due to competition or client pausing discretionary spend?
• Clarify client concentration metrics (e.g., INR 20m+ clients sequentially down).
• Management response
• TMT bottoming out is driven mainly by new deals from existing clients; pipeline is “significant.”
• They avoid over-blaming clients, but cite a shift in TMT spend mix: AI capex up (opex pressure), leading to adjustments in TMT budgets.
• They confirm the INR 20m+ client count sequentially slipped due to one TMT client moving below the threshold (TTM view nuance).
• Notable signals
• Strong recovery framing but no quantitative TMT guidance; relies on “sequential” improvement and pipeline already “in the bag.”
• Some metric framing (TTM vs full-year view) used to contextualize client count volatility.

Theme B: Cogentiq monetization—deal nature, revenue share, and targets

• Core questions
• Is Cogentiq revenue product-led vs services-heavy?
• How big is Cogentiq revenue expected to be by FY27?
• License revenue share is ~3%—how should it evolve?
• Management response
• Cogentiq deals are “product-led”; FDE/implementation may exist but revenue is primarily product-led.
• They expect license revenues to go “north of” 3% and Cogentiq revenue to become more significant, but no FY27 numeric target.
• They plan to report Cogentiq revenue quarterly but are still “figuring out exactly how to do” reporting classification.
• Notable signals / evasiveness
• No explicit FY27 Cogentiq revenue number despite direct questioning.
• Reporting methodology uncertainty (“we will figure it out”) is a partial evasiveness risk.

Theme C: Vertical outlook and FY27 growth trajectory (HLS deceleration, BFSI/Europe hires)

• Core questions
• HLS growth appears to decelerate—how to think about FY27 trajectory?
• Which verticals will contribute meaningfully?
• Management response
• HLS is still strong but lower than prior quarter; overall growth excluding TMT is 35% (vs headline 20%).
• If TMT stabilizes, overall growth should rise.
• Growth is expected “across all verticals,” with new leadership hires (e.g., Chief Practice Officer for BFSI, head of Europe) to accelerate Europe growth.
• Notable signals
• Clear attribution: headline growth is depressed mainly by TMT; HLS deceleration is acknowledged but not treated as structural.

Theme D: Margins, R&D intensity, and operating leverage path

• Core questions
• How will adjusted EBITDA margin improve—does it depend on TMT recovery?
• Medium-term R&D as % of sales; can it increase?
• R&D productivity and margin discipline?
• Management response
• They emphasize operating leverage via SG&A reduction and scaling of Analytics Vidhya/Fractal Alpha.
• R&D: they reiterate a plan to increase R&D to up to ~10% of revenue, but only on the back of expanded gross margins.
• Outcome/output/license mix: they cite 42% currently and want 60% over next few quarters; expect margin expansion from mix shift.
• Notable signals
• Margin improvement narrative is tied to mix shift + scaling, not solely TMT.
• They provide a directional target (60% mix) but not a margin number.

Theme E: Qure.ai and Fractal Alpha segment profitability

• Core questions
• Why Fractal Alpha loss increased (Analytics Vidhya/Fractal Alpha loss up to INR 14 crore)?
• How is Qure.ai growth progressing given associate losses?
• Adjusted EBITDA margin trajectory vs sequential changes.
• Management response
• Fractal Alpha loss increase is due to investment/restatement (iqigai/EdTech team moved into Analytics Vidhya); not a one-time cost.
• Asper revenue timing: contract signing vs subscription revenue recognition implies 2H strength.
• Qure.ai: revenue up 160% YoY; backlog up to Rs.100+ crore; profitability should improve.
• Notable signals
• They explicitly frame the loss as investment + timing, and cite backlog as a leading indicator for Qure.ai.

4. Guidance / Outlook

Explicit guidance (quantitative)

• TMT: “expect healthy sequential growth in TMT the next quarter” (qualitative direction; no numeric).
• Outcome/output/license mix: management states they are at 42% and want 60% over the next few quarters.
• R&D intensity: plan to take R&D to as much as 10% of revenue (conditional on gross margin expansion).
• Asper timing: “we expect the second half of fiscal year to be much stronger for Asper” (timing guidance, not revenue).

Implicit signals (qualitative)

• FY27 growth: management implies headline growth will improve as TMT bottoms out and demand shifts toward AI foundations/transformation.
• Cogentiq monetization: expects license/product revenues to rise, but is still refining reporting and conversion assumptions.
• Profitability: operating leverage should continue as SG&A % declines and Fractal Alpha scales.

5. Standout Statements (direct / high-signal)

• TMT recovery
• “TMT performance is bottoming out and we expect healthy sequential growth in TMT the next quarter.”
• Cogentiq monetization
• “we see these as product-led. Most of these revenues are product led.”
• Demand/AI macro thesis
• “Enterprises are moving AI into their core budget.”
• “Everyone will see some work vanishing… but the work that is coming through is so huge that it more than makes up for that.”
• Operating leverage + mix
• “we are inching gradually forward… and we want to get it to 60 over the next few quarters.”
• R&D discipline
• “We will do it only on the back of expanded margins.”
• Confidence level
• “We have never been more optimistic about where this business is going.”

6. Red Flags / Positive Signals

Red flags
– No numeric FY27 guidance despite multiple questions on vertical trajectory and Cogentiq revenue size.
– Cogentiq reporting ambiguity: “we are just figuring this out exactly how to do” for quarterly Cogentiq revenue reporting—can reduce transparency.
– Reliance on sequential recovery (TMT) without hard targets; risk that “bottoming out” may slip.

Positive signals
– Strong customer metrics (NPS up, NRR up, 0% churn in Q1).
– Clear profitability expansion while increasing R&D.
– Use of leading indicators: Asper ARR growth, Qure.ai backlog jump, Cogentiq pipeline/early wins.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current call tone: More Optimistic
• Prior call (Q4/FY2026, May 12 2026): very bullish about enterprise AI takeoff; emphasized platform compounding and margin expansion.
• Shift now: still bullish, but with more explicit near-term caveats (TMT decline, wage increment timing, segment restatements). Management now focuses more on execution speed + go-to-market reorganization and less on “everything is accelerating” without qualification.

b. Tracking Past Commitments vs Outcomes

1. License revenue target (3% → 20% by 2030)
2. Past statement (May 12 2026): “license driven revenue from 3% to 20% by 2030.”
3. Current call: license revenues still ~3% of revenue; management says it will “go north of that” and expects it to rise, but no intermediate FY27 number.
4. Status: ⏳ Delayed / not yet evidenced in near-term metrics (still at ~3%).
5. Outcome/output/license mix trajectory
6. Past statement (May 12 2026): expected to reach ~60% of revenue to be output/outcome/license in next 2–3 years (Aditi question).
7. Current call: now says 42% currently and wants 60% over the next few quarters.
8. Status: ⏳ Ambitious acceleration vs prior “2–3 years” framing; credibility depends on execution and reporting consistency.
9. TMT outlook
10. Past call (May 12 2026): TMT decline attributed to client-specific issues; expectation to do better in next few quarters.
11. Current call: TMT still negative YoY (-22%) but “bottoming out” and expecting sequential improvement.
12. Status: ⏳ Partially delayed (still a drag in Q1 FY27).

c. Narrative Shifts

• From “platform compounding” to “go-to-market reorganization + execution speed”
• Current call introduces new Chief Commercial Officer and reorganized vectors (AIT/AIF/AIW) as a response to rapidly shifting demand.
• More emphasis on “product-led Cogentiq”
• Earlier calls discussed Cogentiq promise; now management is more explicit that Cogentiq revenues are product-led and expects it to become significant.
• TMT is now treated as a near-term cycle
• Management frames TMT as “bottoming out,” whereas earlier it was more about specific client issues.

d. Consistency & Credibility Signals

• Medium credibility
• Positives: management provides clearer causal explanations (TMT spend mix shift; contract timing; restatement vs one-time costs).
• Concerns: some targets are re-timed/accelerated (mix trajectory) and Cogentiq reporting is still being defined, which can obscure progress.

e. Evolution of Key Themes

• Demand / AI adoption: Improving/still strong (core budget narrative reinforced).
• Margins: Improving and more stable (gross margin 46%, EBITDA margin 17%).
• R&D: Increasing but framed as disciplined and tied to gross margin expansion.
• Expansion via platforms/products: Stronger emphasis on Cogentiq monetization and Fractal Alpha scaling.

f. Additional Insights (cross-period intelligence)

• Management’s “bottoming out” language for TMT appears to be a repeatable pattern: TMT was already a known issue in FY2026 and remains negative YoY in Q1 FY27, suggesting the cycle may be longer than initially implied.
• The company is simultaneously pushing higher mix targets (60% soon) while also acknowledging timing lags (Asper contract-to-revenue, Qure.ai backlog-to-revenue). This can create a gap between narrative and near-term financial realization.